IVA
Inventiva
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
IVA Profile
Inventiva S.A.
A clinical-stage biopharmaceutical company that developing oral small molecule therapies for non-alcoholic steatohepatitis
Biological Technology
Invalid Date
07/10/2020
NASDAQ Stock Exchange
114
12-31
Depository Receipts (Ordinary Shares)
50 rue de Dijon, 21121 Daix France
--
Inventiva S.A. was established in 2011 and incorporated in 2016. The Company is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis or NASH, mucopolysaccharidases or MPS and other serious diseases with unmet medical needs. The company has established a pipeline supported by a discovery engine with an extensive proprietary molecular library, a wholly-owned R&D facility and a team with extensive expertise and experience in developing compounds targeting nuclear receptors, transcription factors and epigenetic regulation.